Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1783 | Thyroid cancer | ICEECE2012

Regulation of hPTTG expression and phosphorylation: autocrine interactions with growth factors in thyroid cells

Lewy G. , Ryan G. , Read M. , Fong J. , Seed R. , Sharma N. , Smith V. , Kwan P. , Stewart S. , Warfield A. , Melmed S. , Eggo M. , Franklyn J. , McCabe C. , Boelaert K.

Introduction: The human Pituitary Tumor Transforming Gene (hPTTG) is a phosphorylated proto-oncogene induced in multiple tumour types. hPTTG phosphorylation is mediated by cyclin-dependent kinase 2 (CDC2) and expression is regulated by specificity protein 1 (SP1). In thyroid cancer, hPTTG induces genetic instability and propagates growth through induction of growth factors (GFs).Methods: The interplay between hPTTG phosphorylation, SP1 regulation and GF ...

ea0029p1060 | Male Reproduction | ICEECE2012

Testosterone replacement therapy: A comparison of testosterone mixed esters, extended release testosterone implants and testosterone undecanoate depot

Conaglen Helen M. , Yarndley Tania , Kamp Jozef , Paul Ryan G , Nirmalaraj Kingsley , Elston Marianne S , Conaglen John V

Introduction: Male hypogonadism is one of the most common endocrine disorders affecting 5.6% of men aged between 30–79 years. Testosterone deficiency (TD) is an independent risk factor for multiple cardiovascular risk factors including obesity, diabetes mellitus, hypertension, dyslipidaemia and endothelial dysfunction. The aims of testosterone replacement treatment (TRT) in hypogonadism are to improve or ameliorate the clinical features and to restore the serum T to physi...